As WA ferries falter, a hydrofoil water taxi makes waves in Seattle
The Brief
The FF-12 water taxi, developed by Artemis Technologies, is an all-electric, hydrofoiling vessel designed to deliver faster, quieter and more energy-efficient trips across the water.
The Belfast-based company recently held a demonstration run between Bremerton and Port Orchard. A route that normally would take around 10 minutes was completed in just two minutes and thirty seconds.
With a $2.5 million price tag — about 1.5 times the cost of a traditional diesel boat — it's not cheap.
SEATTLE - As Washington's ferry system continues to face a shortage of vessels and resources, and water taxi runs across Puget Sound are increasingly cut back, commuters are left searching for reliable alternatives.
Now, a futuristic-looking vessel docked at Seattle's Bell Harbor Marina may signal a breakthrough.
Keep reading to learn more about this new kind of vessel and how it could become the future of Seattle's public marine transit.
The EF-12 water taxi, developed by Artemis Technologies, is an all-electric, hydrofoiling vessel designed to deliver faster, quieter, and more energy-efficient trips across the water. (FOX 13 Seattle)
What is the EF-12 water taxi, and what can it do?
Big picture view
The EF-12 water taxi, developed by Artemis Technologies, is an all-electric, hydrofoiling vessel designed to deliver faster, quieter and more energy-efficient trips across the water.
FOX 13 Seattle got a firsthand look at the high-tech craft on Monday and what could become the future of public marine transit.
"Not only can these boats be greener and cleaner than the current ferries here like the high-speed ferries with Kitsap Transit and King County, they can also be cheaper for the taxpayer." David Tyler, co-founder of Artemis Technologies
A vessel that uses less energy
Local perspective
The Belfast-based company recently held a demonstration run between Bremerton and Port Orchard. A route that normally would take around 10 minutes was completed in just two minutes and thirty seconds — all for the cost of a few dollars in electricity.
According to Tyler, the EF-12 uses hydrofoiling technology — essentially underwater wings — to lift the boat above the surface, dramatically reducing drag. This e-foiling system allows the vessel to cruise up to one meter above the water. Not only does that make for a smoother ride, but it's also significantly more energy efficient.
"We're using anywhere between 70 and 90% less energy," noted Tyler.
At full capacity, the EF-12 now on display in Seattle seats 30 people, but Artemis has bigger plans. They've signed a manufacturing partnership with Delta Marine in Seattle to build a larger version that can carry up to 149 passengers, comparable in size to current Kitsap fast ferries and King County water taxis.
The EF-12 water taxi, developed by Artemis Technologies, is an all-electric, hydrofoiling vessel designed to deliver faster, quieter, and more energy-efficient trips across the water. (FOX 13 Seattle)
A 'game changer for maritime transport'
Dig deeper
Tyler describes the boat as a "game changer for maritime transport," combining aerospace-style flaps, high-voltage electric batteries from the auto sector and yacht racing hydrofoil technology.
The vessel is so fast, it even outpaced FOX 13 Seattle's drone camera during Monday's demo.
"It's very quiet … electric motor … so you can have a conversation with the person next to you," said Tyler. "It's a really amazing way to travel on board the water."
The sleek, futuristic design may remind some of a sci-fi movie or a James Bond scene. And with a $2.5 million price tag — about 1.5 times the cost of a traditional diesel boat — it's not cheap. But Tyler insists the upfront cost pays off quickly. He argues a busy operator could pay back in three years with what they save on fuel.
The EF-12 water taxi, developed by Artemis Technologies, is an all-electric, hydrofoiling vessel designed to deliver faster, quieter, and more energy-efficient trips across the water. (FOX 13 Seattle)
Zero operational carbon emissions
Big picture view
With aging fleets across the state and rising pressure to decarbonize, Tyler says the interest is already strong.
"We've been contacted by certain people here," he shared. "They're excited about the opportunity given the funding, and they're really looking for the right solutions."
"There's aging fleets everywhere," he added. "A lot of people are looking to decarbonize their operations, but I think sometimes they have trouble to know which direction to go in."
Artemis Technologies is hoping to provide that direction, offering what they claim is the world's first commercially viable e-foiling system for marine transport that produces zero operational carbon emissions.
"There's definitely less pollution. There's no oil, no diesel going into the water," said Tyler. "That's really why we're here: to support that fleet to transition to a greener future."
With Washington often called the ferry capital of the U.S., Tyler sees Seattle as a natural fit.
"Seattle has an amazing ferry community because of the natural geography … ferry transport really makes sense."
The Source
Information in this story came from Artemis Technologies and FOX 13 Seattle's original reporting.
MORE NEWS FROM FOX 13 SEATTLE
Inmate escapes police at Seattle-Tacoma International Airport
Jamie Tompkins claims Seattle police scandal was a setup. Here's why
3 small WA businesses voted most worth a 1-hour drive
2 new trails connect Redmond transit station to King County park
WA joins lawsuit against RFK Jr., Trump administration for dismantling HHS
To get the best local news, weather and sports in Seattle for free, sign up for the daily FOX Seattle Newsletter.
Download the free FOX LOCAL app for mobile in the Apple App Store or Google Play Store for live Seattle news, top stories, weather updates and more local and national news.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
19 minutes ago
- Business Upturn
Why are Tata Motors shares falling nearly 5% today? Know More
By Aditya Bhagchandani Published on June 16, 2025, 09:42 IST Shares of Tata Motors Ltd plunged over 4.6% to ₹679.15 on Monday, June 16, after Jaguar Land Rover (JLR) issued a weaker-than-expected financial outlook for FY26 during its latest investor presentation. The stock opened lower and continued to slide, touching an intraday low of ₹679.10. Tata Motors' UK-based luxury car subsidiary JLR stated that it now expects its EBIT margin for FY26 to be in the range of 5–7%, down sharply from the earlier guidance of 10%. This comes as a disappointment to investors, particularly as the company had reported a strong EBIT margin of 10.7% in Q4FY25. In addition to the margin downgrade, JLR said it anticipates free cash flow to be close to zero in FY26, although it expects year-on-year improvement in FY27 and FY28. The update has raised concerns about the near-term profitability and cash generation of the company's luxury vehicle arm, which has been a key driver of growth in recent quarters. At 9:40 AM, Tata Motors' stock was trading at ₹679.15, down 4.62% from the previous close of ₹712.05. The company's market capitalization stood at ₹2.51 lakh crore. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.


Business Wire
41 minutes ago
- Business Wire
HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation
TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter 'HekaBio') today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter 'Alfresa Holdings'), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The partnership aims to accelerate the commercialization of innovative medical products in Japan. HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation -- Accelerating Access to Innovative Therapies in Japan through Alfresa Group's 'Total Supply Chain Service'-- Share Background and Purpose In recent years, Japan has implemented policy reforms to address the growing access gap, where innovative therapies approved overseas are slow to come to the Japanese market. In response to these developments, HekaBio has focused on introducing cutting-edge pharmaceuticals, medical devices, and regenerative medicine products from global markets into Japan and the Asia-Pacific markets. Leveraging a proprietary global network and partnership model, HekaBio evaluates over 200 assets annually across oncology, cardiology and CNS, and supports end-to-end commercialization from licensing to clinical and regulatory development, manufacturing and sales. This partnership with Alfresa Group will enable HekaBio to advance and expand its portfolio and impact, particularly in CNS and regenerative medicine where Alfresa Group has strengths in manufacturing and in sales, including various other aspects of sales-related operations across the supply chain. Outlook Through this partnership, HekaBio and Alfresa Group aim to accelerate the introduction of high-impact, potential blockbuster therapies into the Japanese market, expanding treatment options for patients. The companies also plan to explore commercialization strategies across the Asia-Pacific region and beyond. About HekaBio HekaBio is a Japan-based, asset-light healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage, de-risked opportunities in CNS, oncology, and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, visit About Alfresa Holdings Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, 'we create and deliver a fresh life for all,' the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. For more information:


Business Wire
an hour ago
- Business Wire
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on or about July 9, 2025. We learned that Vivo Capital's counsel informed the paying agent that Vivo would challenge the dividend and asked the paying agent to withdraw from facilitating the distribution of the US$55.00 dividend declared by the SINOVAC Board to all valid shareholders. The SINOVAC Board has an obligation to answer this Petition on behalf of all SINOVAC common shareholders to stand up to the egregious actions of Prime Success. We expect to file our Opposition Brief today at 5:00 p.m. Atlantic Standard Time, followed by a hearing on Wednesday, June 18. We continue to be shocked by the self-serving, unnecessary actions by Advantech and Vivo Capital (together known as the 'Dissenting Investor Group') against SINOVAC, threatening the rightful dividend payment to all valid SINOVAC common shareholders. These incomprehensible actions are unacceptable to the SINOVAC Board because: The Dissenting Investor Group has already pocketed more than US$1.1 billion in dividends from SINOVAC's operating subsidiary, while all SINOVAC's valid shareholders received nothing. An amount equal to the aggregate amount of cash that would be payable under the US$55.00 per common share special dividend in respect of the 2018 PIPE shares has been set aside by the SINOVAC Board in an escrow account managed by an independent third party pending final resolution of the legal proceedings, which the Dissenting Investor Group initiated. Thus, there is no risk whatsoever that the Dissenting Investor Group's allocations of the dividend will not be paid if the courts ultimately decide in their favor regarding the PIPE shares. These new actions by the Dissenting Investor Group go against their assertions of their support of the US$55.00 dividend payment in their letters to shareholders and raises the question – how can you trust anything they say in their letters or press releases? The SINOVAC Board will continue to fight these frivolous lawsuits, all of which aim to accomplish one thing: to allow the Dissenting Investor group to double dip on dividends. We feel certain we will prevail quickly in this and other proceedings. The SINOVAC Board is on a mission to restore fairness and deliver value to ALL SINOVAC shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of filings, hearings and other litigation-related matters, all of which are difficult to predict and many of which are beyond the Company's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.